Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, announced today that the U.S. Food and Drug Administration (FDA) has .
Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies, today announced that a successful scientific advice meeting was held with .
Bloomsbury Genetic Therapies Outlines Pre-Clinical Data on CNS Programs Presented at the American Society of Gene and Cell Therapy 26th Annual Meeting London, UK, 18 May 2023 – Bloomsbury Genetic Therapies Limited, a clinical-stage biotechnology company developing potentially curative treatments for patie.
Bloomsbury Genetic Therapies launches with Seed financing of £5 million to develop potentially curative gene therapy treatments for rare neurological and metabolic diseasesLondon, UK, 7 October 2022 – Bloomsbury Genetic Therapies Limited (“Bloomsbury”), a biotechnology company developin.